Purpose: Elderly patients with esophageal cancer who are not candidates for
chemoradiation may benefit from targeted agents; hence erlotinib combined with …

This study compared the efficiency and safety of radiotherapy plus erlotinib with concurrent
chemoradiotherapy (CCRT) based on paclitaxel plus cisplatin in elderly esophageal cancer …

Objective To evaluate the safety and efficacy of radiation plus erlotinib in patients with
esophageal cancer older than 70 years. Methods Radiotherapy was prescribed at a daily …

The survival rate associated with esophageal cancer is very poor due to diagnosis at
advanced stages of disease and insensitivity to chemotherapy. This study investigated the …

Concurrent chemoradiotherapy is the standard treatment for patients with locally advanced
esophageal squamous cell carcinoma. However, a number of patients present intolerance to …

Introduction: Esophageal adenocarcinoma (EC) is increasing in incidence. Chemoradiation
(CRT) is regarded as an acceptable alternative to surgery for the management of locally …

This phase I trial investigates the safety of combining radiation, 5-fluorouracil (5-FU) and
cisplatin with the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, in …

Importance Palliative radiotherapy (RT) is generally recommended for older patients with
esophageal squamous cell carcinoma (ESCC) with poor prognosis. A new combination …

BACKGROUND: Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor
(EGFR) have activity in solid tumors. The authors evaluated an oral EGFR TKI, erlotinib, in …

Background: Although the prevalence of esophageal cancer increases in elderly patients, its
clinical history and outcome after treatment remain poorly described. Methods: Between …